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Abstract 
A series of novel compounds as candidates for OLED applications were synthesized by 
cyclization reactions of neighbouring rings in dipyrazolo[3,4-b:4',3'-e]pyridines 8-12. The 
desymmetrization of these molecules leading to 14 can be performed using both 
KOH/isoquinoline or palladium catalysts. The resulting structures contain a helical arrangement 
of four different rings. 
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Introduction   
 
In our previous reports we successfuly used KOH/(iso)quinoline system for the production of 6-
aryl-6H-5,6,7-triazadibenzo[f,h]naphtho[3,2,1-cd]azulenes 3 originating from 4-(2-halophenyl)-
1H-pyrazolo[3,4-b]quinolines 2 (Figure 1).1  
 
 
 
Figure 1. 1 s-indacene; 2 4-(2-halophenyl)-1,3-diphenyl-1H-pyrazolo[3,4-b]quinoline; 3 6-
phenyl-6H-5,6,7-triazadibenzo[f,h]naphtho[3,2,1-cd]azulene, with atomic numbering; 4 
dibenzo[a,l]pyrene. 
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These new dyes are characterized by the presence of a seven-membered ring adjoining 
aromatic moieties and may be of interest for luminescent or electroluminescent applications. 
Similar arrangements of rings can be found in a variety of biologically active compounds,2a novel 
nucleosides,2b carbon nanotubes as so called Stone-Wales defects,3 or in recently synthesized 
dimeric triazadibenzo[cd,g]azulenes.4 These angularly arranged rings in 3 impose helicity on the 
molecules and should prevent to some extent their aggregation in the bulk thus extending the 
lifetime of a potential organic light-emitting diode (OLED). This distortion, reminiscent of that 
encountered in either dibenzo[a,l]pyrene5 DB[a,l]P 4, or benzo[c]phenanthrene ([4]helicene),6 is 
the result of strongly interacting protons at the positions 1,15 and 11,12 in 3, respectively. 
Recently, 3,12-dimethoxy-7,8-dicyano[5]helicene was evaluated as a novel emissive material for 
organic light-emitting diodes.7 In this communication, we report a new series of dyes, modified 
aza s-indacenes 14, derived from 4-(2-halophenyl)-1,3,5,7-tetraaryl-1,7-dihydrodipyrazolo[3,4-
b;4',3'-e]pyridines 8-12. Dipyrazolopyridine derivatives have recently been extensively tested as 
promising blue emitters in OLEDs.8 The emission maxima of newly designed dyes are shifted to 
a longer wavelength.   
 
 
Results and Discussion   
 
 
 
Scheme 1 
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Pyrazolo[3,4-b]quinoline 2 (PQ) has two possible sites for cyclization (Figure 1). In the case of 
(iso)quinoline/KOH this preference is meaningless: always a seven-membered ring is formed.1 
Palladium-assisted ring closure is not so obvious: in some cases there are negligible amounts of 
seven-membered isomers formed apart from the main five-membered ring products.1a This holds 
true if the substituent at the 6-position of the PQ skeleton is not bulky enough, or secondary 
amine. These precautions were kept in mind when we turned our attention to 1,3,4,5,7-
pentaphenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridines. These interesting aza analogues of s-
indacene 1 have a plane of symmetry, thus they are devoid of the aforementioned obstacles. 
Therefore, it was tempting to use our procedure to create the novel annulated systems 14, 1,3,5-
triphenyl-2,3,4,5,6-pentaazadibenzo[4,5:6,7]cyclohepta[1,2,3-cd]s-indacenes, abbreviated as 
TPPACI. The aforementioned bispyrazolo[3,4-b:4',3'-e]pyridines can be obtained in several steps 
(4, 3 or 2) starting from commercially available aromatic carboxylic acids, methyl benzoates 5 or 
aroylacetonitriles 6 (Scheme 1). Finally, these by treatment with phenylhydrazine in boiling 4 M 
hydrochloric acid, gave aminopyrazoles 7. The reaction of these with 2-halobenzaldehydes in 
sulfolane delivered precursors 8-13. However the conversion from 7 to 8-13 did not always go in 
the same way. Condensation of 7c (R1 = OMe) with 2-bromobenzaldehyde yielded the expected 
product 13c only in a trace amount (TLC). After replacement of the aldehyde with its chloro 
analogue we obtained 12c in 21% yield after column purification. Reaction of pyrazole 7a with 
2-halobenzaldehydes delivered 8a and 9a, in 35% and 32% yields respectively, which did not 
require chromatographic isolation. The preparation of both tert-butylated analogues of 
bispyrazolopiridines 10-11b did not encounter any problems either, although chromatographic 
purification was performed to afford the pure products. The rationale to prepare bromo 
derivatives was to attempt a ring closure under palladium catalysis to avoid drastic conditions. 
First to afford TPPACI we cyclized (KOH, isoquinoline, method A) our intermediates 8-12 as in 
previous reports.1 We observed that bromo-analogues reacted faster (1 hour). For chloro 
derivatives, 2 hours were required to complete the conversion. Generally, reaction times were 
shorter, because the 2-halophenyl moiety has two neighboring phenyls to be attacked, compared 
to one in 4-(2-halophenyl)-1H-pyrazolo[3,4-b]quinolines 2.1 Palladium-assisted cyclization 
performed (method B) on 9a and 11b delivered the targets after 5 hours in good yields. The 
progress of reaction could be easily monitored by TLC: intensely blue emitting spots of 9a and 
11b were converted to less polar TPPACI of yellow emission. Compound 14b was more soluble 
than 14a and 14c. It also had a high melting point (Table 1).  
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Scheme 2 
 
The above results encouraged us to try a double cyclization to obtain 17a (Scheme 2). The first 
attempt was not satisfactory, because the target compound was extremely insoluble in all 
common organic solvents (mp > 350 °C). It could only be dissolved in boiling DMAC, DMSO 
or 1-methyl-2-pyrrolidinone. Taking into account the solubility studies performed on TPPACI 
we introduced a tertiary butyl to make the compound 17b amenable for further treatment. Indeed, 
this moiety improved the solubility substantially and we were able to record both 1H and 13C 
NMR spectra. It also had a high melting point (339–341 °C). The absorption (λabs) and 
luminescence (λfl) data of the annulated compounds are summarized in Table 1. One can observe 
a slight bathochromic shift in the peak maximum of absorbance in going from 14a to 14c, and a 
'jump' of 70 nm for completely cyclized 17b. A similar effect was also found for the emission 
peak maximum. The quantum yields decreased from 0.50 for 14a to 0.32 for 14c. These data are 
in the range of already reported values.8d The smaller quantum yield of yellow-orange 
fluorescence 17b falls within the range of red emitting benzo[a]aceanthrylene derivatives.9  
 
Table 1. Preparation of TPPACI and 17b from bispyrazolo[3,4-b;4',3'-e]pyridines 8-12,16b and 
photophysical properties of investigated compounds in cyclohexane (see Experimental Section). 
Entry 
Method, Yield (%) 
TPPACI λabs [nm] λfl [nm] Φfl Mp (°C) 
A B 
8a 83 - 
14a 440 520 0.50 282-284 
9a 99 92 
10b 60 - 
14b 444 525 0.45 320-322 
11b 51 74 
12c 85 - 14c 452 547 0.32 291-293 
16b 81 - 17b 459, 487, 522 576 0.08 339-341 
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Conclusions 
 
In summary, a new and general synthesis of heterocyclic indacenes was developed using two 
methods: a classical approach based on KOH/isoquinoline and, using milder conditions, 
employing Pd2(dba)3/P(t-Bu)3 catalytic systems. We also obtained a trisubstituted octacyclic 
azarene 17b, which could possibly be used as a fluorescent core10 to generate novel and 
interesting dendrimers. Further studies are in due course to expand the scope of the present 
method (palladium cyclization of chlorinated analogues of bispyrazolo[3,4-b;4',3'-e]pyridines), 
and to use the products for further conversion as well as for LED purposes. 
 
 
Experimental Section   
 
General. 1H NMR and 13C NMR spectra were recorded using a Mercury-Vx 300 MHz Varian 
operating at 300 and 75MHz, respectively, in CDCl3 with tetramethylsilane (TMS) as an internal 
standard. Elementary analyses were performed on a Perkin-Elmer 2400 CHN analyzer. Melting 
points were measured on a Melt-Temp II instrument. The purity of the compounds obtained was 
checked by TLC. Methyl benzoates 5 were commercially available or were synthesized by 
heating the corresponding acids at reflux with MeOH in the presence of concentrated sulfuric 
acid. 3-Oxonitriles 6 were produced by reaction of the esters with acetonitrile in the presence of 
60% suspension of sodium hydride in toluene.11 Aminopyrazoles 7 and 15 were prepared 
following the method described in the literature.12 Finally, bispyrazolopyridines 8-12 and 16a,b 
were obtained via reported methods.13 Absorption (λabs) and emission (λabs) measurements were 
carried out using a scanning spectrophotometer UV-VIS 2101 (Shimadzu) and a conventional 
fluorescence spectrometer supplied with the cooled photomultiplier EMI 955 8B, respectively. 
Emission quantum yields (Φfl) were measured using quinine sulfate in 0.05M H2SO4 solution as 
an actinometer. Both the optical absorption and fluorescence spectra were measured at room 
temperature in cyclohexane with the molar concentration of the dyes being about 10−5 M in each 
case.  
 
4-(2-Chlorophenyl)-1,3,5,7-tetraphenyl-1,7-dihydrodipyrazolo[3,4-b;4',3'-e]pyridine (8a). 
Yield 2.02 g (35%); light yellow solid; mp = 251–253 °C; Rf = 0.55 (toluene); 1H NMR (CDCl3, 
300 MHz) δ 6.79 (td, 1H, J = 7.5, 1.2 Hz), 6.88−6.94 (m, 2H), 6.99−7.05 (m, 5H), 7.11−7.18 (m, 
6H), 7.34 (t, 2H, J = 7.5 Hz), 7.58 (t, 4H, J = 7.5 Hz), 8.55 (d, 4H, J = 8.4 Hz); 13C NMR 
(CDCl3, 75 MHz) δ 112.68, 120.81, 125.66, 125.76, 127.35, 127.77, 128.82, 128.99, 129.07, 
129.87, 131.19, 132.25, 133.04, 133.24, 138.24, 139.60, 147.82, 150.59; Anal. Calcd. for 
C37H24ClN5: C, 77.41; H, 4.21; N,12.20; found: C, 77.21; H, 4.44; N, 12.11.  
4-(2-Bromophenyl)-1,3,5,7-tetraphenyl-1,7-dihydrodipyrazolo[3,4-b;4',3'-e]pyridine (9a). 
Yield 991 mg (32%); yellow solid; mp = 242–243 °C; Rf = 0.34 (toluene/PE, 1:1); 1H NMR 
(CDCl3, 300 MHz) δ 6.82–6.96 (m, 3H), 7.00–7.05 (m, 4H), 7.11–7.18 (m, 7H), 7.34 (t, 2H, J = 
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7.5 Hz), 7.58 (t, 4H, J = 7.5 Hz), 8.55 (d, 4H, J = 8.7 Hz); 13C NMR (CDCl3, 75 MHz) δ 112.55, 
120.79, 123.35, 125.65, 126.31, 127.32, 127.75, 128.99, 129.18, 129.89, 131.25, 132.00, 132.26, 
134.98, 139.61, 139.75, 147.81, 150.61; Anal. Calcd. for C37H24BrN5: C, 71.85; H, 3.91; 
N,11.32; found: C, 72.01; H, 4.06; N, 11.49.  
3,5-Bis-(4-tert-butylphenyl)-4-(2-chlorophenyl)-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-
b;4',3'-e]pyridine (10b). Yield 976 mg (34%); light yellow solid; mp = 274–277 °C; Rf = 0.48 
(toluene/PE, 1:1); 1H NMR (CDCl3, 300 MHz) δ 1.24 (s, 18H, t-Bu), 6.71 (td, 1H, J = 7.5, 1.5 
Hz), 6.82 (td, 2H, J = 9.0, 1.5 Hz), 6.93 (ddd, 1H, J = 9.0, 7.2, 1.8 Hz), 7.02 (d, 4H, J = 8.7 Hz), 
7.07 (d, 4H, J = 8.7 Hz), 7.33 (t, 2H, J = 7.5 Hz), 7.57 (t, 4H, J = 7.5 Hz), 8.56 (d, 4H, J = 8.4 
Hz); 13C NMR (CDCl3, 75 MHz) δ 31.17, 34.42, 112.85, 120.69, 124.21, 125.49, 128.58, 128.76, 
128.96, 129.14, 129.35, 131.19, 133.00, 133.23, 138.30, 139.74, 147.94, 150.61, 150.67; Anal. 
Calcd. for C45H40ClN5: C, 78.76; H, 5.87; N, 10.20; found: C, 78.60; H, 6.04; N, 10.01.  
4-(2-Bromophenyl)-3,5-bis-(4-tert-butylphenyl)-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-b; 
4',3'-e]pyridine (11b). Yield 2.16 g (29%); light yellow solid; mp = 270–272 °C; Rf = 0.62 
(toluene); 1H NMR (CDCl3, 300 MHz) δ 1.23 (s, 18H, t-Bu), 6.74–6.87 (m, 3H), 7.00–7.04 (m, 
5H), 7.06 (d, 4H, J = 8.7 Hz), 7.33 (t, 2H, J = 7.5 Hz), 7.57 (t, 4H, J = 7.5 Hz), 8.57 (d, 4H, J = 
9.0 Hz); 13C NMR (CDCl3, 75 MHz) δ 31.16, 34.41, 112.70, 120.64, 123.27, 123.35, 124.17, 
125.47, 126.04, 128.85, 128.95, 129.12, 129.36, 131.23, 131.74, 134.91, 139.73, 139.80, 147.93, 
150.62; Anal. Calcd. for C45H40BrN5: C, 73.96; H, 5.52; N, 9.58; found: C, 73.61; H, 5.72; N, 
9.69.  
4-(2-Chlorophenyl)-3,5-bis-(4-methoxyphenyl)-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-b; 
4',3'-e]pyridine (12c). Yield 1.48 g (21%); deep yellow solid; mp = 247–249 °C; Rf = 0.24 
(CHCl3); 
1H NMR (CDCl3, 300 MHz) δ 3.73 (s, 6H, OMe), 6.55 (d, 4H, J = 9.0 Hz), 6.82–6.91 
(m, 2H), 6.97–7.09 (m, 6H), 7.33 (t, 2H, J = 7.5 Hz), 7.56 (t, 4H, J = 7.5 Hz), 8.53 (d, 4H, J = 
9.0 Hz); 13C NMR (CDCl3, 75 MHz) δ 55.23, 112.60, 112.92, 114.53, 120.71, 124.77, 125.50, 
125.84, 128.94, 129.76, 130.26, 131.29, 133.19, 133.29, 138.22, 139.64, 147.56, 150.56, 
159.264; Anal. Calcd. for C39H28ClN5O2: C, 73.87; H, 4.45; N, 11.04; found: C, 74.07; H, 4.62; 
N, 10.91.  
 
General procedure for the preparation of the TPPACIs (method A) 
9a (500 mg, 0.808 mmol), powdered KOH (1.5 g, 27 mmol) and isoquinoline (10 mL) were 
heated at reflux for 1 hour. After cooling water (50 mL) was added. The mixture was extracted 
with toluene (2 x 50 mL). Organic phase was washed with 4 M HCl (2 x 25 mL) and finally with 
saturated aqueous NaCl solution. After drying (Na2SO4) the solvent was removed to dryness and 
the yellow residue was dissolved in CHCl3. The product was precipitated by a slow addition of 
MeOH. For 8a the same amounts of reagents were used, however the mixture was heated at 
reflux for 2 hours. 
3,5-Dihydro-1,3,5-triphenyl-2,3,4,5,6-pentaazadibenzo[4,5:6,7]cyclohepta[1,2,3-cd]s-indacene 
(14a). Yield 430 mg (99%) from 9a and 390 mg (83%) from 8a; yellow solid; mp = 282–284 °C; 
Rf = 0.47 (toluene/PE); (note: about 7 mg of 14a can be dissolved in 0.87 mL of CDCl3 at room 
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temperature); 1H NMR (CDCl3, 300 MHz) δ ; 13C NMR (CDCl3, 75 MHz) δ 6.83 (ddd, 1H, J = 
8.1, 7.2, 1.2 Hz), 7.25 (dd, 1H, J = 8.1, 1.2 Hz), 7.28−7.38 (m, 6H), 7.50−7.61 (m, 6H), 
7.65−7.71 (m, 3H), 7.88−7.94 (m, 1H), 8.38−8.45 (m, 1H), 8.52 (d, 2H, J = 8.7 Hz), 8.56 (d, 2H, 
J = 8.7 Hz); Anal. Calcd. for C37H23N5: C, 82.66; H, 4.31; N, 13.03; found: C, 82.35; H, 4.41; N, 
13.03.  
9-(tert-Butyl)-1-[4-(tert-butyl)phenyl]-3,5-dihydro-3,5-diphenyl-2,3,4,5,6-pentaazadibenzo 
[4,5:6,7]cyclohepta[1,2,3-cd]s-indacene (14b). Yield 227 mg (51%) from 11b and 284 mg 
(60%) from 10b; deep yellow solid after column purification; mp = 320–322 °C; Rf = 0.82 
(toluene); 1H NMR (CDCl3, 300 MHz) δ 1.31 (s, 9H, t-Bu), 1.46 (s, 9H, t-Bu), 6.72 (ddd, 1H, J 
= 7.9, 7.2,1.2 Hz), 7.16 (dd, 1H, J = 8.1, 1.2 Hz), 7.23–7.34 (m, 5H), 7.51–7.59 (m, 7H), 7.62 
(dd, 1H, J = 8.1, 1.2 Hz), 7.87 (d, 1H, J = 2.1 Hz), 8.32 (d, 1H, J = 8.1 Hz), 8.52 (d, 2H, J = 8.7 
Hz), 8.53 (d, 2H, J = 8.7 Hz); 13C NMR (CDCl3, 75 MHz) δ 31.31, 31.32, 34.66, 34.96, 109.21, 
119.47, 120.24, 121.08, 124.98, 125.25, 125.56, 126.08, 126.33, 127.35, 128.88, 128.90, 128.94, 
129.10, 129.57, 130.47, 130.54, 132.74, 134.15, 136.03, 137.45, 139.77, 139.94, 140.32, 140.74, 
144.48, 147.01, 150.55, 151.45, 151.88, 152.93; Anal. Calcd. for C45H39N5: C, 83.17; H, 6.05; N, 
10.78; found: C, 82.98; H, 6.00; N, 10.65.  
3,5-Dihydro-9-methoxy-1-(4-methoxyphenyl)-3,5-diphenyl-2,3,4,5,6-pentaazadibenzo 
[4,5:6,7]cyclohepta[1,2,3-cd]s-indacene (14c). Yield 403 mg (85%) from 12c; yellow solid, no 
column required; mp = 291–293 °C; Rf = 0.39 (CHCl3); (note: about 5 mg of 14c can be 
dissolved in 0.87 mL of CDCl3 at room temperature); 
1H NMR (CDCl3, 300 MHz) δ 3.82 (s, 3H, 
OMe), 3.98 (s, 3H, OMe), 6.84 (d, 2H, J = 9.0 Hz), 6.89 (ddd, 1H, J = 8.1,7.2, 1.2 Hz), 7.12 (dd, 
1H, J = 8.7, 2.7 Hz), 7.28−7.37 (m, 4H), 7.42 (d, 1H, J = 2.7 Hz), 7.54−7.63 (m, 6H), 7.74 (dd, 
1H, J = 8.1, 1.2 Hz), 8.35 (d, 1H, J = 8.7 Hz), 8.52 (d, 2H, J = 8.7 Hz), 8.56 (d, 2H, J = 8.7 Hz); 
Anal. Calcd. for C39H27N5O2: C, 78.38; H, 4.55; N, 11.72; found: C, 78.15; H, 4.68; N, 11.68.  
 
Palladium-assisted cyclization of (9a) and (11b) (method B) 
9a (100 mg, 0.162 mmol), Pd2(dba)3 (30 mg, 0.032 mmol, 20% mol) and DBU (0.25 mL) were 
dissolved in dry DMF (10 mL). The mixture was purged with argon for 10 min. Next P(t-Bu)3 
(0.13 mL, 1M in toluene) was added in one portion, which was heated at 130 °C for 5 hours. 
After cooling, water was added and the yellow solid that precipitated was extracted with toluene. 
After drying and concentration, the oily residue was passed through a short column packed with 
alumina. 14a, yield: 80 mg (92%). For 14b: 11b (150 mg, 0.205 mmol), Pd2(dba)3 (37.5 mg, 
0.041 mmol, 20% mol), DBU (0.25 mL), P(t-Bu)3 (0.16 mL, 1M in toluene) and DMF (10 mL). 
Yield 98 mg (74%). 
 
Preparation of doubly annulated aza s-indacenes 
The precursors 16a and 16b were prepared as for 8-12. 
3,5-Bis(2-chlorophenyl)-1,4,7-triphenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (16a). 
Yield 1.18 g (26%); colorless solid; mp = 264–266 °C; Rf = 0.59 (toluene); 1H NMR (CDCl3, 
300 MHz) δ 6.64 (t, 2H, J = 7.2 Hz), 6.83–6.89 (m, 3H), 7.02–7.13 (m, 6H), 7.19–7.24 (m, 2H), 
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7.34 (t, 2H, J = 7.5 Hz), 7.58 (t, 4H, J = 7.5 Hz), 8.53 (d, 4H, J = 8.7 Hz); 13C NMR (CDCl3, 75 
MHz) δ 113.37, 120.90, 125.72, 125.95, 126.02, 127.72, 128.89, 128.99, 129.54, 129.62, 131.03, 
131.64, 132.40, 134.15, 139.58, 142.50, 145.02, 150.42; Anal. Calcd. for C37H23Cl2N5: C, 73.03; 
H, 3.81; N, 11.51; found: C, 72.95; H, 3.91; N, 11.60.  
4-(4-tert-Butylphenyl)-3,5-bis-(2-chlorophenyl)-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-
b;4',3'-e]pyridine (16b). Yield 1.84 g (28%); colorless solid; mp = 297–300 °C; Rf = 0.59 
(toluene); 1H NMR (CDCl3, 300 MHz) δ 1.13 (s, 9H, t-Bu), 6.62 (d, 2H, J = 8.7 Hz), 6.70 (d, 
2H, J = 8.1 Hz), 6.97−7.08 (m, 6H), 7.16 (dd, 2H, J = 6.6 Hz), 7.34 (t, 2H, J = 7.2 Hz), 7.58 (t, 
4H, J = 8.7 Hz), 8.54 (d, 4H, J = 8.7 Hz); 13C NMR (CDCl3, 75 MHz) δ 31.01, 34.19, 113.48, 
120.85, 122.76, 125.65, 125.89, 127.95, 128.80, 128.97, 129.12, 129.38, 131.70, 132.39, 134.16, 
139.64, 142.83, 145.12, 150.44, 150.51; Anal. Calcd. for C41H31Cl2N5: C, 74.09; H, 4.70; N, 
10.54; found: C, 74.21; H, 4.65; N, 10.50.  
11-tert-Butyl-2,4-diphenyl-2,4-dihydro-1,2,3,4,5-pentaazatribenzo[3,4:5,6:7,8]heptaleno 
[2,1,10,9-cdef]s-indacene (17b). 16b (500 mg, 0.753 mmol), KOH (2.53 g, 45 mmol) and 
isoquinoline (10 mL) were heated at reflux for 2 hours. After cooling, water (50 mL) was added, 
followed by toluene (50 mL). The inorganic phase was discarded, and isoquinoline was extracted 
with 4 M HCl. The organic phase was washed with saturated aqueous NaCl (50 mL) and dried 
(K2CO3). After evaporation, the solid residue was dissolved in toluene and passed through a 
short column packed with alumina. After evaporation of the volatiles the red crystals were 
dissolved in chloroform and MeOH was added dropwise with stirring. The red amorphous solid 
was filtered off. Yield 359 mg (81%); Rf = 0.76 (toluene); mp = 339–341 °C; 1H NMR (CDCl3, 
300 MHz) δ 1.41 (s, 9H, t-Bu), 7.20–7.23 (m, 2H), 7.30 (t, 2H, J = 7.2 Hz), 7.42–7.49 (m, 4H), 
7.53 (t, 4H, J = 7.2 Hz), 7.55 (s, 2H), 8.31–8.34 (m, 2H), 8.45 (d, 4H, J = 8.7 Hz); 13C NMR 
(CDCl3, 75 MHz) δ 30.94, 34.76, 113.21, 120.76, 125.48, 126.21, 128.59, 128.88, 129.10, 
130.94, 131.03, 132.85, 134.44, 137.33, 139.71, 140.07, 142.43, 144.84, 152.44, 153.26; Anal. 
Calcd. for C41H29N5: C, 83.22; H, 4.94; N, 11.84; found: C, 83.42; H, 4.83; N, 11.80.  
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